180 related articles for article (PubMed ID: 21867368)
1. Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma.
Foyil KV; Kennedy DA; Grove LE; Bartlett NL; Cashen AF
Leuk Lymphoma; 2012 Mar; 53(3):506-7. PubMed ID: 21867368
[No Abstract] [Full Text] [Related]
2. Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation.
Ordemann R; Stöhlmacher J; Beuthien-Baumann B; Platzek I; van den Hoff J; Kroschinsky F; Middeke JM; Platzbecker U; Zietz C; Bornhäuser M; Ehninger G
Ann Hematol; 2013 Jan; 92(1):125-7. PubMed ID: 22820970
[No Abstract] [Full Text] [Related]
3. Safety and effective salvage regimen comprising a novel combination of brentuximab vedotin, L-asparaginase, and dexamethasone for refractory anaplastic large cell lymphoma, anaplastic lymphoma kinase negative.
Kawamoto K; Suzuki T; Kasami T; Kiryu M; Sone H; Miyoshi H; Ohshima K; Takizawa J
Hematol Oncol; 2019 Apr; 37(2):212-214. PubMed ID: 30394560
[No Abstract] [Full Text] [Related]
4. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
5. [Treatment strategy of Hodgkin lymphoma].
Nagai H
Rinsho Ketsueki; 2014 Oct; 55(10):1941-51. PubMed ID: 25297759
[No Abstract] [Full Text] [Related]
6. Sequential intensive treatment with the F-MACHOP regimen (+/- radiotherapy) and autologous stem cell transplantation for primary systemic CD30 (Ki-1)--positive anaplastic large cell lymphoma in adults.
Fanin R; Silvestri F; Geromin A; Cerno M; Infanti L; Zaja F; Barillari G; Savignano C; Rinaldi C; Damiani D; Baccarani M
Leuk Lymphoma; 1997 Jan; 24(3-4):369-77. PubMed ID: 9156668
[TBL] [Abstract][Full Text] [Related]
7. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
Pardal E; Coronado M; Martín A; Grande C; Marín-Niebla A; Panizo C; Bello JL; Conde E; Hernández MT; Arranz R; Bargay J; González-Barca E; Pérez-Ceballos E; Montes-Moreno S; Caballero MD
Br J Haematol; 2014 Nov; 167(3):327-36. PubMed ID: 25066542
[TBL] [Abstract][Full Text] [Related]
8. Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature.
Alig SK; Dreyling M; Seppi B; Aulinger B; Witkowski L; Rieger CT
Eur J Haematol; 2015 Jun; 94(6):554-7. PubMed ID: 24913471
[TBL] [Abstract][Full Text] [Related]
9. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
[TBL] [Abstract][Full Text] [Related]
10. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Horwitz S; O'Connor OA; Pro B; Illidge T; Fanale M; Advani R; Bartlett NL; Christensen JH; Morschhauser F; Domingo-Domenech E; Rossi G; Kim WS; Feldman T; Lennard A; Belada D; Illés Á; Tobinai K; Tsukasaki K; Yeh SP; Shustov A; Hüttmann A; Savage KJ; Yuen S; Iyer S; Zinzani PL; Hua Z; Little M; Rao S; Woolery J; Manley T; Trümper L;
Lancet; 2019 Jan; 393(10168):229-240. PubMed ID: 30522922
[TBL] [Abstract][Full Text] [Related]
11. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
Oregel KZ; Everett E; Zhang X; Nagaraj G
Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
[TBL] [Abstract][Full Text] [Related]
12. Treatment of relapsed non-Hodgkin's lymphoma after BEAM chemotherapy and autologous transplantation by BU/CY chemotherapy and salvage transplantation.
Fetscher S; Lübbert M; Kanz L; Behringer D; Finke J; Mertelsmann R; Lange W
Bone Marrow Transplant; 1997 Mar; 19(5):527-8. PubMed ID: 9052926
[TBL] [Abstract][Full Text] [Related]
13. [Intensive treatment of T-cell-rich B lymphoma].
Azaceta G; Palomera L; Varo MJ; Soria J
Sangre (Barc); 1998 Feb; 43(1):94-5. PubMed ID: 9577190
[No Abstract] [Full Text] [Related]
14. First experience of using Brentuximab vedotin and modified program NHL-BFM-90 in the front-line treatment of patient with anaplastic large-cell lymphoma: a case report and a review of literature.
Chernova NG; Zvonkov EE; Badmazhapova DS; Sinitsyna MN; Grebenyuk LA; Sidorova YV; Kostina IE; Kovrigina AM; Obukhova TN; Sudarikov AB; Savchenko VG
Ter Arkh; 2018 Aug; 90(7):77-81. PubMed ID: 30701926
[TBL] [Abstract][Full Text] [Related]
15. High-dose chemotherapy and autologous transplantation in lymphomatous polyposis in second remission: three case reports and literature review.
Popescu RA; Wotherspoon AC; Cunningham D
Bone Marrow Transplant; 1998 Jul; 22(1):103-6. PubMed ID: 9678804
[TBL] [Abstract][Full Text] [Related]
16. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma.
Kaiser U; Uebelacker I; Abel U; Birkmann J; Trümper L; Schmalenberg H; Karakas T; Metzner B; Hossfeld DK; Bischoff HG; Franke A; Reiser M; Müller P; Mantovani L; Grundeis M; Rothmann F; von Seydewitz CU; Mesters RM; Steinhauer EU; Krahl D; Schumacher K; Kneba M; Baudis M; Schmitz N; Pfab R; Köppler H; Parwaresch R; Pfreundschuh M; Havemann K
J Clin Oncol; 2002 Nov; 20(22):4413-9. PubMed ID: 12431962
[TBL] [Abstract][Full Text] [Related]
17. Successful mobilisation of blood stem cells following previous autologous bone marrow transplantation.
McQuaker IG; Haynes AP; Iqbal A; Russell NH
Bone Marrow Transplant; 1996 Jul; 18(1):263-4. PubMed ID: 8832036
[No Abstract] [Full Text] [Related]
18. Impressive response to pegylated liposomal doxorubicin after allogeneic transplantation in a multi-relapsed Hodgkin's lymphoma.
Pellegrini C; Maglie R; Argnani L; Pileri S; Zinzani PL
Hematol Oncol; 2016 Mar; 34(1):49-51. PubMed ID: 25243375
[No Abstract] [Full Text] [Related]
19. Intensified therapy followed by autologous stem-cell transplantation (ASCT) versus conventional therapy as first-line treatment of follicular lymphoma: a meta-analysis.
Wang B; Ren C; Zhang W; Ma X; Xia B; Sheng Z
Hematol Oncol; 2013 Mar; 31(1):29-33. PubMed ID: 22488650
[TBL] [Abstract][Full Text] [Related]
20. The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma.
García-Sanz R; González-López TJ; Vázquez L; Hermida G; Graciani IF; San Miguel JF
Eur J Haematol; 2010 Mar; 84(3):266-70. PubMed ID: 19912314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
